SCHEMBL6296244

SCHEMBL6296244

CC(C)C(=O)C=Cc1cc(F)cc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.47
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
EGFR P00533 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD11B1 P28845 1/20 0.38
SNCA P37840 1/20 0.38
APP P05067 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
ALOX5 P09917 1/20 0.36
NFKB1 P19838 1/20 0.36
STAT3 P40763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296243 1.00 BACE1 (0.47) BACE1PTGS1PTGS2EGFRMEN1
SCHEMBL6297607 0.85 APP (0.40) BACE1MEN1KMT2AAPPHDAC3
SCHEMBL6297608 0.85 APP (0.40) BACE1MEN1KMT2AAPPHDAC3
SCHEMBL6302997 0.83 CCR2 (0.43) PTGS1PTGS2EGFRMEN1KMT2A
SCHEMBL6302999 0.83 CCR2 (0.43) PTGS1PTGS2EGFRMEN1KMT2A
SCHEMBL6296643 0.82 NFE2L2 (0.55) PTGS1PTGS2NFE2L2ALDH1A1SMN1; SMN2
SCHEMBL6296644 0.82 NFE2L2 (0.55) PTGS1PTGS2NFE2L2ALDH1A1SMN1; SMN2
SCHEMBL6297840 0.81 HSD11B1 (0.62) MEN1KMT2AHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL6297842 0.81 HSD11B1 (0.62) MEN1KMT2AHSD11B1ALDH1A1SMN1; SMN2
SCHEMBL24622059 0.78 GLA (0.52) BACE1PTGS1PTGS2EGFRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD BACE1 42/4885PTGS1 2866/4885PTGS2 3523/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD BACE1 42/4885PTGS1 3003/4885PTGS2 3676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.